|
|
Prepublished online as a Blood First Edition Paper on March 27, 2003; DOI 10.1182/blood-2003-01-0014.
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2003, Vol. 102, No. 3, pp. 810-813
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia
Jorge Nieva,
Kelly Bethel, and
Alan Saven
From the Division of Hematology/Oncology and Department of Pathology, Scripps Clinic, La Jolla, CA; and the Scripps Cancer Center, La Jolla, CA
Hairy cell leukemia (HCL) is an indolent B-cell neoplasm, strongly expressing CD20. Despite initial very high response rates following cladribine, many patients (pts) ultimately relapse. Having relapsed after prior treatment with cladribine, 24 HCL pts (21 male, 3 female) with a median age of 53.5 years were treated with rituximab at 375 mg/m2 intravenously weekly for 4 weeks. Of the pts, 3 (13%) achieved complete remissions and 3 (13%), partial responses. Thus, 6 (25%) of 24 pts achieved a response following rituximab. At a median follow-up of 14.6 months, 2 responders have relapsed; median time to relapse was not yet reached. The only grade III or IV toxicities demonstrated were culture-negative febrile neutropenia, transient and reversible disseminated intravascular coagulation related to rituximab administration, and a diverticular abscess, each in single patients. Of 18 nonresponders, 9 pts subsequently received other treatments; 5 pts were retreated with cladribine, 3 underwent splenectomy, and 1 received pentostatin. Follow-up data are available on 7 of these 9 patients; all 7 patients achieved improvements in hematologic parameters. Rituximab, administered at this dose and schedule, has only modest single-agent activity in cladribine-failed HCL patients when compared with other agents active in this disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. J. Kreitman, M. Stetler-Stevenson, I. Margulies, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
J. Clin. Oncol.,
June 20, 2009;
27(18):
2983 - 2990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zenhausern, M. Simcock, A. Gratwohl, U. Hess, M. Bargetzi, A. Tobler, and on behalf of the Swiss Group for Clinical Cancer R
Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)
Haematologica,
September 1, 2008;
93(9):
1426 - 1428.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Golomb
Hairy Cell Leukemia: Treatment Successes in the Past 25 Years
J. Clin. Oncol.,
June 1, 2008;
26(16):
2607 - 2609.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi, J. L. Jorgensen, S. M. O'Brien, S. Verstovsek, C. A. Koller, S. Faderl, F. J. Giles, A. Ferrajoli, W. G. Wierda, S. Odinga, et al.
Eradication of minimal residual disease in hairy cell leukemia
Blood,
June 15, 2006;
107(12):
4658 - 4662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Arons, I. Margulies, L. Sorbara, M. Raffeld, M. Stetler-Stevenson, I. Pastan, and R. J. Kreitman
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
Clin. Cancer Res.,
May 1, 2006;
12(9):
2804 - 2811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
J. Clin. Oncol.,
September 20, 2005;
23(27):
6719 - 6729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
